Tetraphase's failed antibiotic is NOT a novel class of compounds, as is Brilacidin. It would be competition for Brilacidin only in that it' would have been another available antibiotic (which would be good for the world to have), but its novelty is in the fact that it was completely synthetic -- but a member of the same family of antibiotics as tetracycline, which is pretty much useless against many infections now because of antibiotic resistance.

Quote:

---

https://en.wikipedia.org/wiki/Eravacycline
Eravacycline (TP-434) is a synthetic halogenated tetracycline class antibiotic in development by Tetraphase Pharmaceuticals. It is closely related to tigecycline .

---